Literature DB >> 15627255

Polymorphism of paracetamol: relative stabilities of the monoclinic and orthorhombic phases inferred from topological pressure-temperature and temperature-volume phase diagrams.

Philippe Espeau1, René Céolin, Josep-Lluis Tamarit, Marc-Antoine Perrin, Jean-Pierre Gauchi, Franck Leveiller.   

Abstract

The thermodynamic relationships between the two known polymorphs of paracetamol have been investigated, and the subsequent pressure-temperature and temperature-volume phase diagrams were constructed using data from crystallographic and calorimetric measurements as a function of the temperature. Irrespective of temperature, monoclinic Form I and orthorhombic Form II are stable phases at ordinary and high pressures, respectively. The I and II phase regions in the pressure-temperature diagram are bordered by the I-II equilibrium curve, for which a negative slope (dp/dT approximately -0.3 MPa x K(-1)) was determined although it was not observed experimentally. This curve goes through the I-II-liquid triple point whose coordinates (p approximately 234 MPa, T approximately 505 K) correspond to the crossing point of the melting curves, for which dp/dT values of +3.75 MPa x K(-1) (I) and +3.14 MPa x K(-1) (II) were calculated from enthalpy and volume changes upon fusion. More generally, this case exemplifies how the stability hierarchy of polymorphs may be inferred from the difference in their sublimation curves, as topologically positioned with respect to each other, using the phase rule and simple inferences resorting to Gibbs equilibrium thermodynamics. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15627255     DOI: 10.1002/jps.20261

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Effect of particle size and compression force on compaction behavior and derived mathematical parameters of compressibility.

Authors:  Sarsvatkumar Patel; Aditya Mohan Kaushal; Arvind Kumar Bansal
Journal:  Pharm Res       Date:  2006-10-25       Impact factor: 4.200

2.  A new method of producing monoclinic paracetamol suitable for direct compression.

Authors:  Andrey G Ogienko; Elena V Boldyreva; Andrey Yu Manakov; Vladimir V Boldyrev; Alexander S Yunoshev; Anna A Ogienko; Svetlana A Myz; Alexei I Ancharov; Andrey F Achkasov; Tatiana N Drebushchak
Journal:  Pharm Res       Date:  2011-06-14       Impact factor: 4.200

3.  Heterogeneous nucleation of polymorphs on polymer surfaces: polymer-molecule interactions using a Coulomb and van der Waals model.

Authors:  Nanna Wahlberg; Anders Ø Madsen; Kurt V Mikkelsen
Journal:  J Mol Model       Date:  2018-06-09       Impact factor: 1.810

4.  Collective many-body van der Waals interactions in molecular systems.

Authors:  Robert A DiStasio; O Anatole von Lilienfeld; Alexandre Tkatchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-24       Impact factor: 11.205

5.  Empirically augmented density functional theory for predicting lattice energies of aspirin, acetaminophen polymorphs, and ibuprofen homochiral and racemic crystals.

Authors:  Tonglei Li; Shaoxin Feng
Journal:  Pharm Res       Date:  2006-08-23       Impact factor: 4.200

6.  Modelling temperature-dependent properties of polymorphic organic molecular crystals.

Authors:  Jonas Nyman; Graeme M Day
Journal:  Phys Chem Chem Phys       Date:  2016-11-16       Impact factor: 3.676

7.  Interactions Between Paracetamol and Hypromellose in the Solid State.

Authors:  Edyta Leyk; Marek Wesolowski
Journal:  Front Pharmacol       Date:  2019-01-24       Impact factor: 5.810

8.  X-ray and Thermal Analysis of Selected Drugs Containing Acetaminophen.

Authors:  Izabela Jendrzejewska; Tomasz Goryczka; Ewa Pietrasik; Joanna Klimontko; Josef Jampilek
Journal:  Molecules       Date:  2020-12-13       Impact factor: 4.411

9.  Prediction and Preparation of Coamorphous Phases of a Bislactam.

Authors:  Luke I Chambers; Osama M Musa; Jonathan W Steed
Journal:  Mol Pharm       Date:  2022-06-22       Impact factor: 5.364

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.